-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hepatocellular carcinoma (HCC) patients are often accompanied by liver cirrhosis, and its severity is generally assessed by Child-Pugh classification
.
Most clinical trials for systemic treatment of HCC are limited to Child-Pugh A patients, including the Phase 3 CELESTIAL trial of cabozantinib in HCC
Hepatocellular carcinoma (HCC) patients are often accompanied by liver cirrhosis, and its severity is generally assessed by Child-Pugh classification
The patients were randomly divided into two groups 2:1, the cabozantinib group (60 mg orally per day) or placebo
.
To assess the clinical outcome of patients in the CELESTIAL study with ALBI grade 1 or 2 at baseline
The patients were randomly divided into two groups 2:1, the cabozantinib group (60 mg orally per day) or placebo
Among 707 patients, they were randomized 2:1 to receive cabozantinib (60 mg per day) or placebo.
In ALBI level 1 patients, cabozantinib improved the median OS of patients compared with placebo by 17.
OS
OSAmong ALBI grade 1 patients, cabozantinib also improved the median PFS of patients compared with placebo, which were 6.
5 months (95% CI 5.
6-7.
4) and 1.
9 months (95% CI 1.
9-2.
2) (HR 0.
42, 95% CI) 0.
32–0.
56); in ALBI level 2 patients, cabozantinib improved the median PFS of patients compared with placebo, which were 3.
7 months (95% CI 3.
5-4.
3) and 1.
9 months (95% CI 1.
8-1.
9) (HR 0.
46) , 95% CI 0.
37–0.
58)
.
5 months (95% CI 5.
6-7.
4) and 1.
9 months (95% CI 1.
9-2.
2) (HR 0.
42, 95% CI 0.
32–0.
56); in ALBI level 2 patients, cabozantinib improved the median PFS of patients compared with placebo, which were 3.
7 months (95% CI 3.
5-4.
3) and 1.
9 months (95% CI 1.
8-1.
9) (HR 0.
46) , 95% CI 0.
37–0.
58)
.
Among ALBI grade 1 patients, cabozantinib also improved the median PFS of patients compared with placebo, which were 6.
PFS
PFSIn both subgroups, the ORR of the cabozantinib group was 4%; in the ALBI level 1 subgroup, the ORR of the placebo group was 1%, and the ALBI level 2 subgroup was 0%
.
In the two subgroups, the disease control rate (DCR) of cabozantinib was also higher than that of placebo; for ALBI level 1, the DCR of the cabozantinib group was 74% and that of the placebo group was 40%; for ALBI level 2, the DCR was 57.
In both subgroups, the ORR of the cabozantinib group was 4%; in the ALBI level 1 subgroup, the ORR of the placebo group was 1%, and the ALBI level 2 subgroup was 0%
In the ALBI level 1 subgroup, 12% of patients in the cabozantinib group discontinued the study due to treatment-related adverse events (AEs), compared with only 2% in the placebo group
Adverse events
Adverse eventsIn summary, the study shows that no matter ALBI level 1 or 2, cabozantinib is supported in the treatment of previously treated advanced hepatocellular carcinoma (HCC)
.
.
The study shows that no matter ALBI level 1 or 2, cabozantinib is supported in the treatment of previously treated advanced hepatocellular carcinoma (HCC)
Original source:
Robin Kate Kelley, Rebecca Miksad, Irfan Cicin, et al.
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade.
British Journal of Cancer; https://doi.
org/10.
1038/s41416-021- 01532-5
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade.
British Journal of Cancer; https://doi.
org/10.
1038/s41416-021- 01532-5 Leave a message here